First Second Third Forth First Class 1 2,500
Class 1 Class 4 Class 8 Class 6 Second Class 4 3,600
2,500 3,600 1,000 4,500 Third Class 8 1,000
Forth Class 6 4,500
Fifth Sixth Seventh Eighth Fifth Class 3 8,000
Class 3 Class 3 Class 5 Class 2 Sixth Class 3 2,100
8,000 2,100 1,600 5,200 Seventh Class 5 1,600
Eighth Class 2 5,200
Ninth Tenth Eleventh Twelfth Ninth Class 4 1,000
Class 4 Class 1 Class 3 Class 2 Tenth Class 1 1,200
1,000 1,200 4,800 6,300 Eleventh Class 3 4,800
Twelfth Class 2 6,300
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.